Cancer vaccines. Any future?

Archivum Immunologiae et Therapiae Experimentalis

Volumn 59, Issue 4, 2011, Pages 249-259

  Myc, Lukasz A ^a   Gamian, Andrzej ^b   Myc, Andrzej ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Adjuvant; Cytokines; Heteroclitic peptides; Immunoediting; Liposomes; Nanoemulsions; TH1; TH2; Tumor associated antigens; Tumor specific antigens

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; BASILIXIMAB; CANCER VACCINE; CARBOHYDRATE ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOSOME; OVALBUMIN; TUMOR ANTIGEN; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR;

ADOPTIVE TRANSFER; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; GENE GUN IMMUNIZATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NATURAL KILLER CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MICE; MODELS, IMMUNOLOGICAL; NEOPLASMS; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 79959623424     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-011-0129-y     Document Type: Review

References (100)

1. Allison AC (1999) Squalene and squalane emulsions as adjuvants. Methods 19:87-93
2. American Cancer Society (2009) Cancer, Facts & Figures 2009. http://www.cancer.org/downloads/STT/500809web.pdf
3. Banat GA, Christ O, Cochlovius B et al (2001) Tumour-induced suppression of immune response and its correction. Cancer Immunol Immunother 49:573-586 (Pubitemid 33783073)
4. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5:296-306 (Pubitemid 40516155)
5. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252 (Pubitemid 28155090)
6. Banchereau J, Briere F, Caux C et al (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767-811 (Pubitemid 30365397)
7. Baratelli F, Lin Y et al (2005) Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175:1483-1490 (Pubitemid 41023048)
8. Barber MA, Zhang T, Gagne BA et al (2007) NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model. J Immunol 178:6140-6147 (Pubitemid 46717395)
9. Bellone M, Iezzi G, Imro MA et al (1999) Cancer immunotherapy: synthetic and natural peptides in the balance. Immunol Today 20:457-462 (Pubitemid 29476075)
10. Bennett SR, Carbone FR, Toy T et al (1998) B cells directly tolerize CD8(+) T cells. J Exp Med 188:1977-1983
11. Bergmann-Leitner ES, Abrams SI (2001) Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 50:445-455 (Pubitemid 33079340)
12. Bettelli E, Korn T, Oukka M et al (2008) Induction and effector functions of T(H)17 cells. Nature 453:1051-1057 (Pubitemid 351871737)
13. Bielinska AU, Janczak KW, Landers JJ et al (2008) Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retrovir 24:271-281 (Pubitemid 351282102)
14. Blansfield JA, Beck KE, Tran K et al (2005) Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593-598 (Pubitemid 41533093)
15. Borowski AB, Boesteanu AC, Mueller YM et al (2007) Memory CD8+ T cells require CD28 costimulation. J Immunol 179:6494-6503
16. Carbone FR, Kurts C, Bennett SR et al (1998) Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol Today 19:368-373
17. Casares N, Lasarte JJ, de Cerio AL et al (2001) Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol 31:1780-1789 (Pubitemid 32547341)
18. Cazet A, Julien S, Bobowski M et al (2010) Consequences of the expression of sialylated antigens in breast cancer. Carbohydr Res 345:1377-1383
19. Chang CC, Ciubotariu R, Manavalan JS et al (2002) Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3:237-243 (Pubitemid 34218114)
20. Cox JC, Coulter AR (1997) Adjuvants - a classification and review of their modes of action. Vaccine 15:248-256 (Pubitemid 27116125)
21. Darzynkiewicz Z (2006) Will cancer immunotherapy fail? Scientist 20:14 (letter to editor)
22. DeNardo DG, Andreu P, Coussens LM (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 29:309-316
23. Disis ML, Bernhard H, Shiota FM et al (1996) Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88:202-210 (Pubitemid 26230688)
24. Durántez M, López-Vázquez AB, de Cerio AL et al (2009) Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes. Scand J Immunol 69:80-89
25. Eggermont AM (2009) Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 15:6745-6747
26. Ernstoff MS, Crocenzi TS, Seigne JD et al (2007) Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res 13(2 Pt 2):733s-740s
27. Fay JW, Palucka AK, Paczesny S et al (2006) Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother 55:1209-1218 (Pubitemid 43992047)
28. Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3:630-641
29. Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245-273 (Pubitemid 30365381)
30. Fujii S, Liu K, Smith C et al (2004) The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199:1607-1618 (Pubitemid 38821994)
31. Gallichan WS, Rosenthal KL (1996) Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 184:1879-1890 (Pubitemid 26404478)
32. Ghiringhelli F, Ménard C, Terme M et al (2005) CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202:1075-1085 (Pubitemid 41464501)
33. Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118-1122
34. Gupta RK, Rost BE, Relyveld E et al (1995) Adjuvant properties of aluminium and calcium compounds. In: Powell MF, Newman MJ (eds) Vaccine design: the subunit and vaccine approach. Plenum, New York, pp 229-248
35. Gurunathan S, Sacks DL, Brown DR et al (1997) Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 186:1137-1147 (Pubitemid 27441157)
36. Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18:927-974 (Pubitemid 30365401)
37. Han TH, Jin P, Ren J et al (2009) Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma. J Immunother 32:399-407
38. Hayakawa Y, Screpanti V, Yagita H et al (2004) NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol 172:123-129 (Pubitemid 38020463)
39. Huang B, Zhao J, Li H et al (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009-5014 (Pubitemid 40827306)
40. Jäger E, Jäger D, Knuth A (2002) Clinical cancer vaccine trials. Curr Opin Immunol 14:178-182 (Pubitemid 34188476)
41. Janssen EM, Lemmens EE, Wolfe T et al (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421:852-856 (Pubitemid 36254145)
42. Julien S, Picco G, Sewell R et al (2009) Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer 100:1746-1754
43. Kaczmarek R (2010) Alterations of Lewis histo-blood group antigen expression in cancer cells. Postepy Hig Med Dosw 64:87-99
44. Kalams SA, Walker BD (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188:2199-2204 (Pubitemid 29028492)
45. Khazaie K, Bonertz A, Beckhove P (2009) Current developments with peptide-based human tumor vaccines. Curr Opin Oncol 21:524-530
46. Ko BK, Kawano K, Murray JL et al (2003) Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 9:3222-3234 (Pubitemid 37082716)
47. Kolar P, Knieke K, Hegel JK et al (2009) CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum 60:123-132
48. Kraman M, Bambrough PJ, Arnold JN et al (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330:827-830
49. Langermann S (1996) New approaches to mucosal immunization. Semin Gastrointest Dis 7:12-18
50. Levine MM, Dougan G (1998) Optimism over vaccines administered via mucosal surfaces. Lancet 351:1375-1376 (Pubitemid 28209992)
51. Levitsky HI, Lazenby A, Hayashi RJ et al (1994) In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 179:1215-1224
52. Marciani DJ (2003) Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8:934-943
53. Martinon F, Krishnan S, Lenzen G et al (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23:1719-1722 (Pubitemid 23218089)
54. Martin-Orozco N, Muranski P, Chung Y et al (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31:787-798
55. McGilvray RW, Eagle RA, Watson NF et al (2009) NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 15:6993-7002
56. McMahan RH, McWilliams JA, Jordan KR et al (2006) Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest 116:2543-2551 (Pubitemid 44330153)
57. Miyahara Y, Odunsi K, Chen W et al (2008) Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 105:15505-15510
58. Motamedi M, Arab S, Moazzeni SM et al (2009) Improvement of a dendritic cell-based therapeutic cancer vaccine with components of Toxoplasma gondii. Clin Vaccine Immunol 16:1393-1398
59. Muller D, Pederson K, Murray R et al (1991) A single amino acid substitution in an MHC class I molecule allows heteroclitic recognition by lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes. J Immunol 147:1392-1397
60. Myc A, Kukowska-Latallo JF, Bielinska AU et al (2003) Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 21:3801-3814 (Pubitemid 37338208)
61. Nakanishi Y, Lu B, Gerard C et al (2009) CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462:510-513
62. Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332 [See comment]
63. Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187-207 (Pubitemid 40174238)
64. Numasaki M, Watanabe M, Suzuki T et al (2005) IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175:6177-6189 (Pubitemid 41508106)
65. Ochsenbein AF (2002) Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther 9:1043-1055
66. Ostrand-Rosenberg S (2008) Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18:11-18
67. Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59:1593-1600
68. Palena C, Schlom J (2010) Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol 2010:380697
69. Pardoll DM (1998) Cancer vaccines. Nat Med 4(5 suppl):525-531
70. Parmiani G, Castelli C, Dalerba P et al (2002) Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 94:805-818
71. Parmiani G, Castelli C, Pilla L et al (2007) Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 18:226-232 (Pubitemid 46323086)
72. Paul S, Acres B, Limacher JM et al (2007) Cancer vaccines: challenges and outlook in the field. IDrugs 10:324-328 (Pubitemid 46675914)
73. Qin Z, Blankenstein T (2000) CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12:677-686
74. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296 (Pubitemid 46697910)
75. Renkvist N, Castelli C, Robbins PF et al (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3-15 (Pubitemid 32250041)
76. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380-384
77. Rosenberg SA, Yang JC, Schwartzentruber DJ et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327 [See comment]
78. Schlom J, Tsang KY, Kantor JA et al (1999) Strategies in the development of recombinant vaccines for colon cancer. Semin Oncol 26:672-682 (Pubitemid 30013274)
79. Schuler-Thurner B, Dieckmann D, Keikavoussi P et al (2000) Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1 + melanoma patients by mature monocyte-derived dendritic cells. J Immunol 165:3492-3496
80. Schuler-Thurner B, Schultz ES, Berger TG et al (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279-1288 (Pubitemid 34564330)
81. Sfanos KS, Bruno TC, Maris CH et al (2008) Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14:3254-3261
82. Shadidi M, Sorensen D, Dybwad A et al (2008) Mucosal vaccination with phage-displayed tumour antigens identified through proteomics-based strategy inhibits the growth and metastasis of 4T1 breast adenocarcinoma. Int J Oncol 32:241-247 (Pubitemid 351176083)
83. Somasundaram R, Jacob L, Swoboda R et al (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62:5267-5272 (Pubitemid 35024601)
84. Speiser DE, Liénard D, Pittet MJ et al (2002) In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 32:731-741
85. Srivastava MK, Sinha P, Clements VK et al (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70:68-77
86. Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21:685-711 (Pubitemid 37174545)
87. Stills HF Jr (2005) Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J 46:280-293
88. Tesniere A, Schlemmer F, Boige V et al (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29:482-491
89. Toes RE, Ossendorp F, Offringa R et al (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753-756 (Pubitemid 29189679)
90. Tüting T, Gambotto A, DeLeo A et al (1999) Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther 6:73-80 (Pubitemid 129667761)
91. Vajdy M, Srivastava I, Polo J et al (2004) Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol 82:617-627
92. van der Burg SH, Bijker MS, Welters MJ et al (2006) Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv Drug Deliv Rev 58:916-930 (Pubitemid 44709262)
93. Vogel FR, Powell MF (1995) A compendium of vaccine adjuvants and excipients. Pharm Biotechnol 6:141-228
94. Waldmann TA (2003) Immunotherapy: past, present and future. Nat Med 9:269-277
95. Yamazaki S, Iyoda T, Tarbell K et al (2003) Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 198:235-247 (Pubitemid 37009740)
96. Zaks TZ, Rosenberg SA (1998) Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu + tumors. Cancer Res 58:4902-4908 (Pubitemid 28503688)
97. Zarei S, Schwenter F, Luy P et al (2009) Role of GM-CSF signaling in cell-based tumor immunization. Blood 113:6658-6668
98. Zhang Z, Sun P, Liu J et al (2008) Suppression of FUT1/FUT4 expression by siRNA inhibits tumor growth. Biochim Biophys Acta 1783:287-296
99. Zhang JP, Yan J, Xu J et al (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50:980-989
100. Zorn E, Hercend T (1999) A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur J Immunol 29:602-607 (Pubitemid 29078521)